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Summary: 2% mupirocin ointment applied intra-nasally for 5 days was 
assessed for elimination of nasal carriage of Staphylococcus aureus in 31 staff 
members in a children’s hospital. Three volunteers failed to complete the 
trial because of side effects, i.e. buccal reddening and swelling, and un- 
pleasant taste. During treatment staphylococcal nasal carriage was not found 
in any case; of the 24 post-treatment nasal swabs taken 4 days after treatment 
22 were still negative. Re-colonization with S. aureus of different phage types 
occurred in the remaining two cases. 
Key words: Nasal staphylococcal carriage; topical mupirocin; pseudomonic 
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Introduction 
Fuller et al. (1971) first recorded the antibacterial activit’y of a group of 
substances produced by fermentation of a strain of Pseudomonasfluorescens. 
Subsequently, the name pseudomonic acid A was ascribed to the major 
metabolite, which accounted for most of the antibacterial activity observed. 
Mupirocin has been accepted as the approved name for pseudomonic acid 
A. Its chemical structure and mode of action has been shown to be differ- 
ent from any known class of antibiotics (Chain & Mellows, 1977; Hughes & 
Mellows 1978 a,b; Alexander et al., 1985). 
Mupirocin has a narrow spectrum of activity, confined mainly to 
gram-positive bacteria, including Staphylococcus aureus, Staphylococcus 
epidermidis, and Streptococcus pyogenes. There is moderate activity against 
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some gram-negative organisms, such as Haemophilus injluenzae and 
Neisseria gonorrhoeae, but it is relatively inactive against enterobacteria and 
enterococci (Sutherland et al., 1985). Casewell & Hill (1985, 1986) 
demonstrated the good in-vitro activity of mupirocin against S. aureus, 
including methicillin-resistant strains and suggested mupirocin as the 
topical agent of choice to eliminate nasal carriage. Bactericidal 
concentrations of mupirocin are achieved by topical administration of a 2% 
formulation in an ointment. This study was carried out to assess the efficacy 
of mupirocin in the elimination of nasal carriage of S. aweus in healthy 
volunteers. 
Materials and methods 
One hundred and eighty-six medical and nursing staff working in clinical 
areas of a children’s hospital were screened for nasal and pharyngeal 
carriage of S. aureus. The organism was isolated from 63 (33.9%), and 31 of 
these staff (nine males and 22 females), who were still positive after a repeat 
nasal swab at 1 week, were enrolled in the study. Informed consent was 
obtained from each subject. 
The topical treatment consisted of pseudomonic acid A 2% w/w as 
calcium salt in an ointment base of soft paraffin containing anhydrous 
lanolin (Beecham Pharmaceuticals, Worthing, England). Volunteers were 
given verbal and written instructions. The ointment was applied in 
match-head size amounts to each nostril by fingertips. After application it 
was distributed by squeezing the nose between finger and thumb. The 
ointment was given four times a day for 5 days. 
The persistence of staphylococcal carriage prior to treatment was 
confirmed by examination of a third nasal and pharyngeal swab. On the 
third day of treatment another swab was taken. Follow-up nasal swabs were 
collected 1 and 4 days after each course. 
All nasal swabs were collected in a standard way by firmly rotating plain 
cotton-wool swabs, soaked in sterilized physiologic saline, around the 
periphery of the anterior nares. All specimens were inoculated on 
blood-agar and on mannitol salt agar plates (Columbia-Blutagar, 
Mannit-Kochsalz-Phenolrot-Agar, Heipha, Heidelberg, FRG) and 
incubated at 37°C for 24 and 48 h. Colonies were identified as S. aweus if 
they showed typical morphology on blood agar, fermentation of mannitol 
salt agar, were gram-positive cocci in clusters and gave a positive reaction of 
the coagulase-slide or coagulase-tube test. Growth of S. aweus was read 
semi-quantitatively, i.e. a scanty, moderate, or heavy growth. 
Phage typing of S. aweus was carried out by Dr. W. Lenz (National 
Reference Center for Staphylococcal Typing, Institute for Medical 
Microbiology, Bonn, Federal Republic of Germany). 
Efficacy of mupirocin 
Results 
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Before treatment, all the 3 1 nasal swabs and 10 (32.3 O/o) of pharyngeal swabs 
were positive for S. aureus. Three volunteers failed to complete the trial; 
one noticed buccal reddening and swelling and wished to stop and two 
found the ointment unpleasant to use. During treatment staphylococcal 
carriage could not be demonstrated in any volunteer; two swab results could 
not be obtained. Follow-up swabs 1 day after treatment failed to yield S. 
UUY~US with one exception or again in two cases swab results were not 
available. Of the 24 post-treatment swabs taken 4 days after the course was 
completed, 22 (91.7%) were still negative for S. aureus, whereas 
recolonization of the anterior nares with S. UUY~US of different phage types 
was found in two volunteers. 
Discussion 
In the present study, mupirocin has been shown promptly to eliminate nasal 
carriage of S. uureus. As suggested in previous studies (Dacre, Emmerson & 
Jenner, 1983; Casewell & Hill, 1986), this topical agent has an important 
role in the elimination of nasal staphylococci. During a small outbreak of 
gentamicin-and methicillin-resistant S. uureus on a urology ward, mupirocin 
was found to be effective in eradicating the multiresistant micro-organism in 15 
nasal carriers (Dacre, et al., 1983). However, the formulation in polyethylene 
glycol was associated with side effects such as localized stinging, soreness, dry 
skin and itching around the nose, noticed by six of the subjects. 
In Casewell & Hill’s study (1986) of 32 healthy volunteers, no significant 
side-effects were observed with a white soft paraffin base formulation. In 
their study S. uwem could not be detected, even in low numbers, in nose 
swabs from any of the volunteers within 2 days of starting mupirocin, and 
even after 5 weeks only six showed recolonization. Ultimately, 14 individuals 
resumed staphylococcal carriage, in most cases with different phage types. 
Similarly encouraging results were found in our study. Elimination of S. 
uzweza from the anterior nares could be found on day 3 of therapy in all 
subjects from whom swabs were available. One week after starting the 
treatment recolonization was noted in only two subjects. Unfortunately, 
further follow-up could not be carried out. However, the prompt 
eradication of nasal carriage by mupirocin within 3 days of treatment was 
impressive, and gave further evidence that it may be useful in controlling 
staphylococcal outbreaks in hospitals. 
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